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Abstract
Loss-of-function mutations in the PINK1 or parkin genes result in recessive heritable forms of parkinsonism. Genetic studies
of Drosophila orthologs of PINK1 and parkin indicate that PINK1, a mitochondrially targeted serine/threonine kinase, acts
upstream of Parkin, a cytosolic ubiquitin-protein ligase, to promote mitochondrial fragmentation, although the molecular
mechanisms by which the PINK1/Parkin pathway promotes mitochondrial fragmentation are unknown. We tested the
hypothesis that PINK1 and Parkin promote mitochondrial fragmentation by targeting core components of the
mitochondrial morphogenesis machinery for ubiquitination. We report that the steady-state abundance of the
mitochondrial fusion-promoting factor Mitofusin (dMfn) is inversely correlated with the activity of PINK1 and Parkin in
Drosophila. We further report that dMfn is ubiquitinated in a PINK1- and Parkin-dependent fashion and that dMfn co-
immunoprecipitates with Parkin. By contrast, perturbations of PINK1 or Parkin did not influence the steady-state abundance
of the mitochondrial fission-promoting factor Drp1 or the mitochondrial fusion-promoting factor Opa1, or the subcellular
distribution of Drp1. Our findings suggest that dMfn is a direct substrate of the PINK1/Parkin pathway and that the
mitochondrial morphological alterations and tissue degeneration phenotypes that derive from mutations in PINK1 and
parkin result at least in part from reduced ubiquitin-mediated turnover of dMfn.
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Introduction
Parkinson’s disease (PD) is a common neurodegenerative
movement disorder caused by the degeneration of dopamine-
secreting neurons in the midbrain. The mechanisms underlying
dopamine neuron degeneration in PD are incompletely under-
stood, although systemic mitochondrial complex I impairment is a
relatively common feature [1], suggesting that mitochondrial
dysfunction plays a major role in PD pathogenesis. Further
support for this model derives from the findings that particular
mitochondrial toxins can elicit PD-like syndromes in humans and
animal models [2,3]; that mitochondrial DNA deletions occur at
high frequency in dopaminergic neurons of aged individuals [4,5],
particularly those with PD [4]; and that several genes implicated in
familial forms of PD influence mitochondrial integrity in model
systems [6,7,8].
Recent work in flies and vertebrates suggests that two of the
genes involved in familial forms of PD, PINK1 and parkin, act in a
common pathway to regulate mitochondrial morphology [6].
PINK1 encodes a mitochondrially targeted serine/threonine
kinase, whereas parkin encodes an E3 ubiquitin-protein ligase. In
Drosophila, loss-of-function mutations in PINK1 and parkin result
in enlarged and swollen mitochondria and degeneration of flight
muscle, sperm and dopaminergic neurons [9,10,11,12,13,14].
These phenotypes can be at least partially suppressed by
increasing the gene dosage of the mitochondrial fission-promoting
factor Drp1, or by decreasing the gene dosage of the mitochon-
drial fusion-promoting factors Opa1 or Mitofusin (dMfn)
[15,16,17,18]. These findings suggest that the PINK1/Parkin
pathway acts to promote mitochondrial fission or inhibit
mitochondrial fusion, either of which would culminate in
mitochondrial fragmentation. PINK1 and Parkin have also been
shown to influence mitochondrial morphology in vertebrates,
although, in contrast to the studies conducted in Drosophila,
mitochondrial fragmentation is the most frequently observed
phenotype upon reduced PINK1 and Parkin activity in mamma-
lian cell culture [19,20,21,22]. While these discordant findings
may reflect differences in the mechanisms by which PINK1 and
Parkin influence mitochondrial morphology in vertebrates and
invertebrates, this possibility has not yet been tested because the
molecular mechanisms by which PINK1 and Parkin influence
mitochondrial morphology are unknown.
In our present work, we tested the hypothesis that PINK1 and
Parkin influence mitochondrial morphology in Drosophila by
acting directly on core components of the mitochondrial fission- or
fusion-promoting apparatus. We report that dMfn is ubiquitinated
in a PINK1- and Parkin-dependent fashion, that the steady-state
abundance of dMfn is inversely correlated to PINK1 and Parkin
activity, and that Parkin co-immunoprecipitates with dMfn.
Together, our findings suggest that dMfn is a direct substrate of
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Parkin activity on mitochondrial morphology and tissue integrity
derive at least in part from reduced ubiquitin-mediated turnover of
dMfn.
Results
To test the hypothesis that Parkin promotes the ubiquitin-
mediated turnover of core components of the mitochondrial
morphogenesis machinery, we sought to explore the effects of
altered Parkin activity on the steady-state abundance of the
mitochondrial fission-promoting factor Drp1 and the mitochon-
drial fusion-promoting factors Opa1 and dMfn. Although
Drosophila encodes a second mitofusin homolog that is expressed
exclusively in the male germline [23,24], we focused on dMfn
because of its broad expression pattern [24]. Because PINK1 acts
genetically upstream of Parkin [11,12,14], we also sought to test
whether alterations in PINK1 activity influence the steady-state
abundance of Drp1, Opa1 and dMfn. To perform these
experiments we generated antisera against Drosophila Drp1 and
dMfn using peptide immunogens corresponding to sequences in
these proteins. Figure 1 shows the results of western blot analysis
using these two affinity-purified antisera, as well as a commercial
antiserum that is able to immunoprecipitate Drosophila Opa1 (see
Materials and Methods section) to test their specificity.
The anti-dMfn antiserum recognizes several bands, including
one of 94 kDa, which corresponds well to the 91–94 kDa sizes of
the predicted dMfn isoforms in Drosophila (Figure 1A). The
abundance of the 94 kDa band recognized by our antiserum is
selectively decreased in flies expressing two different RNAi
constructs targeting the dmfn transcript, indicating that this band
represents dMfn. The other bands detected by our anti-dMfn
antiserum are unaffected by RNAi treatment, suggesting that they
represent nonspecific cross-reacting species.
The anti-Opa1 antiserum detects bands of 80 kDa, 100 kDa
and 105 kDa (Figure 1B). The intensities of all three of these bands
are significantly diminished by double-stranded RNAs targeting
the opa1 transcript, and overexpression of a FLAG-tagged Opa1
construct results in the appearance of more intense 80 kDa and
100 kDa bands. In vertebrates, mature Opa1 protein is proteo-
lytically processed into several lower molecular weight forms in the
mitochondrion [25]. Thus, the 105 kDa Opa1 band may
represent a full-length or near full-length form of Opa1, which is
predicted to be between 107 and 112 kDa in Drosophila, whereas
the 80 kDa and 100 kDa Opa1 bands may correspond to
proteolytically processed forms of this protein. Although we do
not understand why Opa1 overexpression selectively influences the
abundance of only the lower molecular weight Opa1 species, our
findings support the conclusion that this antiserum specifically
recognizes Opa1.
The anti-Drp1 antiserum recognizes bands of 70 and 75 kDa in
Drosophila, which reasonably approximate the 83 kDa predicted
size of this protein (Figure 1C). The intensities of both of these
bands are diminished in a fly strain bearing a heterozygous null
mutation of drp1 and increased in transgenic flies overexpressing
Drp1, indicating that both bands represent Drp1 and that our
antiserum is specific for Drp1. In vertebrates, Drp1 is subjected to
multiple posttranslational modifications, including phosphoryla-
tion, ubiquitination and sumoylation [26]. Thus, the two different
forms of Drosophila Drp1 may derive from a posttranslational
modification, or alternatively an uncharacterized splice variant of
the drp1 gene. Together, our findings indicate that our antisera
against Drp1, Opa1, and dMfn are able to efficiently recognize
these three proteins in Drosophila.
We used our three antisera to compare the steady-state
abundance of Drp1, Opa1, and dMfn in wild-type (wt) flies,
park
25 null mutants, and PINK1
B9 null mutants. These analyses
revealed that dMfn abundance was increased in both park
25 and
PINK1
B9 null mutants relative to wt controls (Figure 2A, B). By
contrast, we did not detect an alteration in the steady-state
abundance or molecular weight of Opa1 or Drp1 in park
25 or
PINK1
B9 null mutants relative to wt controls (Figure 2C, D).
Mutations in PINK1 and parkin also failed to influence the
molecular weight or abundance of several control proteins that
localize to mitochondria, including the b-subunit of mitochondrial
complex V and the mitochondrial voltage-dependent anion
channel (VDAC, also known as porin), indicating that the
increased abundance of dMfn in PINK1 and parkin mutants does
not reflect a general increase in mitochondrial mass (Figure 2).
There was no significant change in the abundance of the dmfn
Figure 1. Western blot analysis showing specificity of antisera
that recognize Drosophila dMfn, Opa1, and Drp1. (A) Protein
extracts from wt flies and flies expressing either the UAS-dmfn-
RNAi
Vienna or UAS-dmfn-RNAi
Guo transgenes targeting the dmfn gene
were subjected to western blot analysis with an anti-dMfn antiserum.
The hsp70-GAL4 driver was used to induce expression of the dmfn-RNAi
transgenes, and flies were collected for analysis 24 to 48 hrs after a 3-hr
heat shock protocol. The arrow indicates the location of the dMfn band
at 94 kDa. The asterisks (*) indicate two nonspecific bands detected at
80 kDa and 110 kDa. (B) Protein extracts from wt flies, flies bearing the
UAS-Opa1-FLAG transgene and the mesoderm-specific 24B-GAL4 driver,
and flies bearing the UAS-opa1RNAi transgene and the muscle-specific
dmef2-GAL4 driver were subjected to western blot analysis with an anti-
Opa1 antiserum. (C) Protein extracts from wt flies, flies bearing the UAS-
Drp1-HA transgene and the muscle-specific dmef2-GAL4 driver, and flies
heterozygous for the Df(2L)Excel6008 deletion chromosome (which
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25 or PINK1
B9 null mutants relative to wt (data
not shown), indicating that mutations in PINK1 and parkin
influence dMfn protein abundance through a posttranscriptional
mechanism.
We also explored the possibility that decreased PINK1 or
Parkin activity might influence the subcellular distribution of
Drp1, which is recruited to mitochondria from the cytoplasm to
promote mitochondrial fission. However, we detected no obvious
alteration in the fraction of Drp1 that distributes with mitochon-
dria in park
25 or PINK1
B9 mutants relative to wt controls
(Figure 2E), although this experiment revealed that the higher
MW form of Drp1 appeared to preferentially localize to
mitochondria in both wt and mutant samples. This finding may
offer insight into the mechanism by which Drp1 is recruited to
mitochondria and will be further explored in future work.
Given that the abundance of dMfn was increased in PINK1 and
parkin mutants, we also tested the effects of PINK1 and Parkin
overexpression on dMfn abundance. These studies revealed that
overexpression of PINK1 or Parkin resulted in decreased dMfn
abundance relative to a wt control (Figure 2F). The effects of
PINK1 and Parkin overexpression appeared to be specific to
dMfn, as we failed to detect any influence of PINK1 or Parkin
Figure 2. Perturbations of PINK1 and parkin specifically influence dMfn abundance. Protein extracts from wt males (m), PINK1
B9
hemizygous males, wt males and females (m and f) and park
25 males and females were subjected to western blot analysis with an affinity-purified
anti-dMfn antiserum (A), an anti-Opa1 antiserum (C), an affinity-purified anti-Drp1 antiserum (D), an anti-complex V b antiserum (A, C, D), an anti-
VDAC antiserum (A, C, D), and an anti-actin antiserum (A, C, D). Arrow in (A) indicates location of the dMfn band at 94 kDa and the asterisks (*)
indicate nonspecific bands. (B) Quantification of dMfn abundance in PINK
B9 and park
25 null mutants relative to wt controls. Because PINK1
B9 males are
sterile and the PINK1 gene resides on the X chromosome, we are only able to generate male PINK1
B9 mutants and thus used wt males as the control
population for these mutants. The ratio of dMfn to actin abundance was obtained from three independent blots for each sample analyzed; the ratios
for wt controls were set at a value of 1 and mutant ratios were normalized to the wt ratios. *p,0.05 by Student’s t-test. (E) Protein extracts from
mitochondrial and cytosolic fractions (see Materials and Methods section for details on fractionation) were subjected to western blot analysis witha n
affinity-purified anti-Drp1 antiserum, an anti-complex V b (CompV) antiserum, an anti-VDAC antiserum, and an anti-actin antiserum. (F) Protein
extracts from wt flies, flies overexpressing Parkin (hsp70-GAL4/UAS-Parkin) and flies overexpressing PINK1 (hsp70-GAL4/UAS-PINK1) were subjected to
western blot analysis with an affinity-purified anti-dMfn antiserum, an anti-complex V b antiserum, an anti-VDAC antiserum, and an anti-actin
antiserum. Flies were subjected to a 1-hr heat shock and collected for analysis 24 hrs following the heat shock. The arrow indicates the location of the
dMfn band at 94 kDa and the asterisks (*) indicate the two nonspecific bands.
doi:10.1371/journal.pone.0010054.g002
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mitochondrial complex V, or of VDAC, which, like dMfn,
localizes to the outer mitochondrial membrane (Figure 2F).
Our finding that the abundance of dMfn is increased in PINK1
and parkin mutants and decreased upon overexpression of PINK1
and Parkin is consistent with the hypothesis that PINK1 and
Parkin promote the ubiquitin-mediated turnover of dMfn. A
prediction of this hypothesis is that a ubiquitinated form of dMfn
exists, at least transiently, in wt flies, and that the abundance of this
ubiquitinated form of dMfn will be substantially decreased in
PINK1 and parkin mutants. To test this prediction, we immuno-
precipated dMfn from wt flies, PINK1 mutants and parkin mutants
and subjected these immunoprecipitates to western blot analysis
with an anti-dMfn and an anti-ubiquitin antiserum. To control for
the specificity of our anti-dMfn antiserum, we also immunopre-
cipated dMfn from flies expressing an RNAi construct targeting
the dMfn transcript and subjected the immunoprecipitate to
western blot analysis with an anti-dMfn and an anti-ubiquitin
antiserum. The anti-ubiquitin antiserum detected a band of
approximately 120 kDa in the immunoprecipitate from wt flies but
detected only a very faint 120 kDa band in flies expressing an
RNAi construct targeting the dMfn transcript (Figure 3), indicating
that a low-abundance form of ubiquitinated dMfn exists in wt flies.
By contrast, the abundance of ubiquitinated dMfn in the dMfn
immunoprecipitates from PINK1
B9 null mutants and park
25 null
mutants was dramatically decreased relative to wt, despite the fact
that more dMfn was immunoprecipitated from PINK1
B9 and park
25
mutants relative to wt (Figure 3). Identical results were obtained
upon repeating these experiments using an independently
generated anti-dMfn antiserum to immunoprecipitate dMfn from
flies of the aforementioned genotypes (Figure S1). Although a small
amount of ubiquitinated dMfn is still detectable in PINK1 null
mutants (Figure 3), this finding is consistent with previous genetic
studies demonstrating that Parkin is able to compensate at least
partially for the loss of PINK1 activity [11,12,14,15]. Moreover,
the finding that dMfn is still weakly ubiquitinated in PINK1 null
mutants provides an explanation for the somewhat less severe
phenotypes of PINK1 null mutants relative to parkin null mutants
[9,10,11,12,13,15].
Our findings are consistent with the model that the PINK1/
Parkin pathway promotes the ubiquitin-mediated turnover of
dMfn. While the simplest interpretation of our findings is that
Parkin directly promotes the ubiquitination of dMfn, we cannot
rule out the possibility that the ubiquitination of dMfn by Parkin
proceeds through an indirect mechanism. To help distinguish
between these models we immunoprecipitated Parkin from wt flies
and subjected the immunoprecipitate to western blot analysis with
an anti-dMfn antiserum. To control for the possible nonspecific
interaction of dMfn with our anti-Parkin antiserum, we also
subjected a protein extract from park
25 null mutants to immuno-
precipitation with an anti-Parkin antiserum and then used this
immunoprecipitate in a western blot analysis with our anti-dMfn
antiserum. These experiments revealed that dMfn co-immuno-
precipated with Parkin in wt flies, but failed to detect a dMfn band
in an immunoprecipitate from park
25 mutants (Figure 4). These
findings indicate that Parkin assembles in a complex with dMfn
and suggest that dMfn is a direct substrate of Parkin.
Discussion
In previous work, we and others showed that genetic
manipulations that promote mitochondrial fragmentation, includ-
ing increased drp1 gene dosage and decreased opa1 or dmfn gene
dosage, dramatically suppress the PINK1 and parkin mutant
phenotypes in Drosophila [15,16,17,18]. These findings, coupled
with previous work demonstrating that PINK1 acts upstream of
Parkin in a common pathway [11,12,14], led us to hypothesize
that PINK1 and Parkin influence mitochondrial integrity by
regulating core components of the mitochondrial morphogenesis
machinery through ubiquitination [15]. Our current results
provide direct support for this hypothesis by demonstrating that
dMfn is ubiquitinated in a PINK1- and Parkin-dependent fashion
and that the steady-state abundance of dMfn is increased in PINK1
and parkin mutants and decreased in PINK1- and Parkin-
overexpressing flies. These findings suggest a model in which
PINK1 phosphorylates either dMfn or Parkin and thereby
increases the efficiency with which Parkin is able to ubiquitinate
dMfn. The subsequent ubiquitin-mediated turnover of dMfn
Figure 3. dMfn is ubiquitinated in a PINK1- and Parkin-dependent fashion. Affinity purified anti-dMfn antiserum was used to
immunoprecipitate dMfn from wild-type flies, PINK1
B9 mutants, and park
25 mutants. As a control for specificity, anti-dMfn antiserum was also used to
immunoprecipitate dMfn from flies with hsp70-GAL4 driven expression of UAS-dmfn-RNAi
Vienna. In the left panel, 3% of the lysate input used in the
immunoprecipitations was subjected to western blot analysis using an anti-ubiquitin antiserum to show that general ubiquitination levels were
similar in all genotypes. In the middle and right panels, dMfn immunoprecipitates from all four genotypes were subjected to western blot analysis
with either anti-ubiquitin antiserum (middle panel) or anti-dMfn antiserum (right panel). Arrow indicates the unmodified dMfn species detected in wt
flies, PINK1
B9 mutants, and park
25 mutants, with reduced levels in flies expressing UAS-dmfn-RNAi
Vienna. Arrowhead indicates location of ubiquitinated
dMfn species. These analyses were replicated at least three times with similar results.
doi:10.1371/journal.pone.0010054.g003
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mitochondrial fragmentation (Figure 5). While our current
findings were in review, another study primarily using cultured
Drosophila S2 cells also reported that dMfn is a substrate of the
PINK1/Parkin pathway, thus providing additional support for our
conclusions [27].
Our previous finding that the PINK1/Parkin pathway promotes
mitochondrial fragmentation led us to propose that this pathway
may act to segregate damaged portions of the mitochondrial
reticulum for turnover through an autophagic mechanism [15].
Several recent studies provide compelling support for this
hypothesis by demonstrating that treatment of cultured vertebrate
cells with mitochondrial damaging agents triggers PINK1 to
selectively recruit Parkin to damaged mitochondria, where Parkin
acts to promote the autophagic turnover of these mitochondria,
presumably by ubiquitinating particular mitochondrial targets
[28,29,30,31]. These studies, together with our current findings
raise the possibility that the selective Parkin-mediated ubiquitina-
tion and subsequent degradation of dMfn on damaged portions of
the mitochondrial reticulum, coupled with ongoing mitochondrial
fission serves to sequester the mitochondrial damage to small
fusion-incompetent mitochondria that are subsequently eliminated
through autophagy (Figure 5). However, the size of ubiquitinated
dMfn suggests that it is triply ubiquitinated and previous work
indicates that a chain of four or more ubiquitins is required for
efficient targeting to the proteasome [32]. Thus, alternative
interpretations of our findings, although not mutually exclusive,
are that ubiquitination of dMfn inactivates the fusion-promoting
activity of dMfn, or serves as a tag marking the damaged
Figure 4. dMfn assembles with Parkin. Affinity purified anti-Parkin
antiserum was used to immunoprecipitate Parkin from wt flies and
park
25 null mutants. As park
25 flies do not produce any Parkin protein,
this immunoprecipitation serves as a control for any nonspecific
binding of other proteins to the anti-Parkin antiserum. Three percent of
the total amount of lysate used for the immunoprecipitations as well as
the Parkin immunoprecipitates were subjected to western blot analysis
with the anti-dMfn antiserum. Only in the wt flies did a band
corresponding to the dMfn band appear indicating an interaction
between Parkin and dMfn. The asterisks (*) indicate the nonspecific
bands.
doi:10.1371/journal.pone.0010054.g004
Figure 5. A potential model by which the PINK1/Parkin pathway promotes mitochondrial fragmentation and turnover. Previous work
has shown that PINK1 localizes to the outer mitochondrial membrane with its kinase domain facing the cytoplasm [28,39], where it is required to
recruit Parkin selectively to damaged mitochondria to promote the autophagic clearance of these mitochondria [27,28,29,30,31]. Our model
postulates that upon Parkin recruitment to damaged portions of the mitochondrial reticulum, it ubiquitinates (Ub) the mitochondrial fusion-
promoting factor Mitofusin, thus tagging it for degradation, or otherwise inactivating its fusion-promoting activity. Subsequent Drp1-dependent
mitochondrial fission would yield a damaged mitochondrial product that is deficient in Mitofusin, and thus unable to re-enter the mitochondrial
network. These small damaged mitochondrial fission products would instead be targeted for autophagic degradation. Although our figure depicts a
model in which Parkin binds prior to mitochondrial fission, Parkin could also be recruited to damaged mitochondria following fission. An alternative
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ubiquitination of a peroxisomal surface protein is sufficient to
signal the autophagic degradation of this organelle [33] is
consistent with our latter model. Experiments are currently
underway to distinguish these possibilities.
While our model in which the PINK1/Parkin pathway
promotes mitochondrial fragmentation through the ubiquitination
of dMfn is completely consistent with previous work on PINK1
and Parkin in Drosophila, recent findings from vertebrate cell
culture studies challenge this model. In particular, several of the
studies of PINK1 in vertebrate systems have found that reduced
PINK1 activity results in mitochondrial fragmentation
[19,20,21,22], suggesting that PINK1 may promote mitochondrial
fusion—exactly the opposite of the conclusion drawn from studies
of the PINK1/Parkin pathway in flies. While additional work will
be required to resolve these apparent conflicts, it is important to
point out that the findings from studies of PINK1 and Parkin in
flies have involved tissues that are profoundly affected by loss of
PINK1 and Parkin activity, whereas the tissue sources of the cells
that have been used in at least some of the conflicting vertebrate
studies are largely unaffected by mutations in PINK1 and parkin.
Thus, a possible explanation for these apparently discordant
findings is that the mitochondrial fragmentation resulting from
reduced PINK1 activity that has been observed in vertebrate
systems involves a compensatory induction of mitochondrial
fragmentation in these cells, which perhaps also explains their
relative insensitivity to the loss of PINK1 activity. In potential
support of this model is the finding that while the mitochondrial
fragmentation seen in PINK1-deficient vertebrate cells can be
rescued by inactivating Drp1, this manipulation enhances the cell
death associated with PINK1 deficiency [21], a finding that is
entirely consistent with work in flies. Future work should resolve
these apparent conflicts and further clarify the influence of
PINK1- and Parkin-dependent ubiquitination of dMfn on
mitochondrial integrity.
Materials and Methods
Fly strains. The UAS-PINK1 [12], UAS-Park [9], UAS-Opa1-
FLAG [16], UAS-Drp1-HA [16], UAS-opa1-RNAi [17], UAS-dmfn-
RNAi
Guo [17], dmef2-GAL4 [34], elav-GAL4 [35], 24B-GAL4 [36]
and hsp70-GAL4 [37] transgenic lines and the park
25 [9] and
PINK1
B9 [12] alleles have all been described previously. A UAS-
regulated RNAi line targeting the dmfn transcript (UAS-dmfn-
RNAi
Vienna) was obtained from the Vienna Drosophila RNAi
Center (Vienna, Austria). The Df(2L)Excel6008 deletion stock,
which removes the drp1 gene, was obtained from the Bloomington
Stock Center (Bloomington, IN).
Heat shock induction protocols. Flies bearing both the
hsp70-GAL4 driver and the GAL4-responsive transgenes of interest
were subjected to heat shock by incubation for 1 hr at 37uC. For
the RNAi transgenes, the flies were incubated a further 2 hrs at
30uC. Following heat shock, flies were either flash frozen in liquid
nitrogen, or maintained at 18uC for varying periods of time before
freezing.
Antisera. Rabbit polyclonal antiserum recognizing
Drosophila Parkin has been previously described [38]. Rabbit
polyclonal antisera recognizing the Drosophila Drp1 and dMfn
were generated by a commercial source (Pocono Rabbit Farm,
Canadensis, PA) using synthetic peptides corresponding to
sequences in these proteins (Drp1: PPAPTRPDSIENST; dMfn:
FTGKVRERSKKGQP). The anti-Drp1 and anti-dMfn antisera
were purified using the synthetic peptides that elicited these
antisera as ligands in affinity chromatography, as described
(ThermoScientific SulfoLink Immobilization Kit for Peptides,
Thermo Scientific (Waltham, MA) #44999). In the course of
testing whether a commercial rabbit antiserum to human
Mitofusin 2 (Sigma (St. Louis, MO) #M6319) would cross-react
with the corresponding fly protein, this antiserum was used to
immunoprecipitate proteins from an adult fly protein extract and
the immunoprecipitate was subjected to tandem mass
spectrometry analysis. This analysis detected 11 Opa1 peptides
(13.7% sequence coverage), but failed to detect peptides
corresponding to either of the two fly Mitofusin proteins.
Additional evidence in support of the specificity of this
antiserum for Opa1 is provided in Figure 1. A mouse
monoclonal anti-ubiquitin antiserum (Ub (P4D1), sc-8017; Santa
Cruz Biotechnology, Santa Cruz, CA) was used to detect
ubiquitinated proteins. Mouse monoclonal antibodies were used
to detect the inner mitochondrial membrane protein OxPhos
Complex V subunit b (Molecular Probes (Eugene, OR) #A
21351), the outer mitochondrial membrane protein porin (VDAC)
(MitoSciences (Eugene, OR) #MSA03) and actin (Chemicon
(Billerica, MA) #MAB1501).
Western blot analyses. Proteins were separated by SDS-
PAGE on either 10% Tris acrylamide gels or NuPAGE 4–12%
Bis-Tris gels (Invitrogen #NP0335) and electrophoretically
transferred onto nitrocellulose or PVDF membranes.
Immunodetections with commercial antibodies were performed
at the following concentrations: rabbit anti-hMfn2 (dOpa1) 1:500,
mouse anti-OxPhos Complex V subunit b 1:20,000, mouse anti-
VDAC 1:1000, mouse anti-actin 1:50,000, mouse anti-ubiquitin
1:500. The secondary antibodies, anti-rabbit HRP and anti-mouse
HRP (Sigma), were used at 1:10,000 and detection of signal
utilized Thermo Scientific electrochemiluminescence (ECL)
reagents. Quantification was performed using the software
program NIH Image 1.62 (National Institutes of Health,
Bethesda, MD) by measuring band density and subtracting
background from an identical-sized region of the scanned image
lacking bands.
Immunoprecipitations. To generate protein extracts for
immunoprecipitation, 100–200 adult flies were frozen in liquid
nitrogen, ground to a fine powder using a chilled mortar and
pestle, transferred to a Dounce homogenizer and homogenized in
1.5 ml of lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1% NP-40, 10% glycerol, 10 mM NaF, 1 mM Na3VO4, 100 mg/
ml PMSF, Sigma protease inhibitor cocktail (Sigma #P8340)).
The resulting lysate was subjected to centrifugation at 12,000 g for
15 minutes at 4uC to remove cuticular material and cell debris.
The protein concentration of the supernatant was adjusted to
2 mg/ml with lysis buffer and incubated with purified dMfn
antisera overnight at 4uC. Protein G Sepharose (GE Healthcare,
Piscataway, NJ) beads were then added to the lysate for 3 hours,
collected by low-speed centrifugation, washed three times in lysis
buffer and boiled in 2X SDS-PAGE sample buffer with 2% beta-
mercaptoethanol for 10 minutes to release immunoprecipitated
dMfn. The boiled sample was then subjected to centrifugation to
pellet the beads and the supernatant was analyzed using western
blot analysis.
Subcellular fractionation. Fifty adult flies were manually
homogenized in a microfuge tube with a small pestle in subcellular
fractionation buffer (220 mM mannitol, 68 mM sucrose, 20 mM
HEPES (pH 7.4), 80 mM KCl, 0.5 mM EGTA, 2 mM
Mg(CH3COO)2, and Sigma protease inhibitor cocktail (Sigma
#P8340)). The homogenate was then transferred to a Dounce
homogenizer and further homogenized with 30 strokes of the
pestle, and then subjected to centrifugation at 1,500 g for 5
minutes at 4uC to prepare a post-nuclear supernatant. The post-
PINK/Parkin Target Mitofusin
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25 minutes at 4uC to pellet mitochondria and yield a post-
mitochondrial supernatant consisting of soluble cytosolic proteins.
The post-mitochondrial supernatant and mitochondrial pellet
were then suspended in SDS-PAGE sample buffer and used in
western blot analysis.
Supporting Information
Figure S1 An independently generated anti-dMfn antiserum
confirms that dMfn is ubiquitinated in a PINK1- and Parkin-
dependent fashion. An anti-dMfn antiserum generated against the
peptide DTVDKSGPGSPLSRF was provided by Dr. Alex
Whitworth and used to immunoprecipitate dMfn from wt flies,
PINK1[B9] mutants, and park[25] mutants. Lysate from flies with
hsp70-GAL4 driven expression of UAS-dmfn-RNAi[Vienna] was
also subjected to immunoprecipitation to confirm the specificity of
the anti-dMfn antiserum provided by Dr. Whitworth. In the left
panel, 3% of the lysate input used in the immunoprecipitations
was subjected to western blot analysis using an anti-ubiquitin
antiserum to show that general ubiquitination levels were similar
in all genotypes. In the middle and right panels, the dMfn
immunoprecipitates derived using the anti-dMfn antiserum
provided by Dr. Whitworth were subjected to western blot
analysis with either anti-ubiquitin antiserum (middle panel) or our
anti-dMfn antiserum (right panel). Arrow indicates the unmodified
dMfn species detected in wt flies, PINK1[B9] mutants, and
park[25] mutants, with reduced levels in flies expressing UAS-
dmfn-RNAi[Vienna]. Arrowhead indicates location of ubiquiti-
nated dMfn species. All analyses shown were repeated twice with
similar results.
Found at: doi:10.1371/journal.pone.0010054.s001 (1.31 MB TIF)
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